Study Enrollment


Your details will not be published or shared.

Clinical Trial

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSONíS DISEASE (TEMPO-1 TRIAL)

The purpose of this research study is to test the safety and effectiveness of the study drug, CVL-751-PD-001, in treating patients with early Parkinsons disease.


Eligibility Criteria

  • Has been diagnosis Parkinsons Disease PD Patient is 40 to 80 years old

Contact Information

    Buff Farrow

    (706) 721-2798

   bfarrow@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.